Advertisement

Stent Thrombosis

  • Javier Cuesta
  • Marcos García-Guimaraes
  • Fernando Rivero
  • Teresa Bastante
  • Fernando Alfonso
Chapter

Abstract

Coronary stents constitute the default strategy during percutaneous coronary intervention (PCI) as they provide improved safety and efficacy compared with balloon angioplasty alone. Stents reduce restenosis rates compared to balloon angioplasty predominantly as a result of a larger acute gain that translates into a greater minimal lumen diameter at follow-up. Although neointimal proliferation is increased after bare metal stent (BMS) implantation, eventually the net lumen gain at follow-up is larger than that obtained with balloon angioplasty. Drug-eluting stents (DES) significantly reduced neointimal proliferation and the need for reinterventions as compared with BMS. In addition, the safety of PCI improved after the introduction of coronary stents that drastically reduced the incidence of abrupt vessel closure. However, stent thrombosis still remains an important and feared complication. This entity has a wide chronological spectrum encompassing anywhere from intra-procedural to many years after implantation.

Keywords

Stent thrombosis Interventional cardiology Coronary angiography Intravascular ultrasound Optical coherence tomography 

References

  1. 1.
    Fischman DL, Leon MB, Baim DS. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331:496–501.CrossRefPubMedGoogle Scholar
  2. 2.
    Serruys PW, de Jaegere P, Kiemeneij F. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489–95.CrossRefPubMedGoogle Scholar
  3. 3.
    Cultip DE, Windecker S, Mehran R. Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:1208–13.Google Scholar
  4. 4.
    Lagerqvist B, James SK, Stenestrand U. SCAAR Study Group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009–19.CrossRefPubMedGoogle Scholar
  5. 5.
    Lagerqvist B, Carlsson J, Fröbert O. Stent thrombosis in Sweden: a report from the Swedish Coronary Angiography and Angioplasty Registry. Circ Cardiovasc Interv. 2009;2:401–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Levine GN, Bates ER, Blankenship JC. ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58:e44–e122.CrossRefPubMedGoogle Scholar
  7. 7.
    Alfonso F, Suarez A, Angiolillo DJ. Findings of intravascular ultrasound during acute stent thrombosis. Heart. 2004;90:1455–9.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Kubo T, Imanishi T, Takarada S. Assessment of culprit lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. J Am Coll Cardiol. 2007;50:933–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Cuesta J, Rivero F, Alfonso F. Ongoing stent thrombosis: optical coherence tomography findings. Rev Esp Cardiol. 2015;68:1024.CrossRefPubMedGoogle Scholar
  10. 10.
    Alfonso F, Dutary J, Paulo M. Combined use of optical coherence tomography and intravascular ultrasound imaging in patients undergoing coronary interventions for stent thrombosis. Heart. 2012;98:1213–20.CrossRefPubMedGoogle Scholar
  11. 11.
    Iakovou I, Schmidt T, Bonizzoni E. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126–30.CrossRefPubMedGoogle Scholar
  12. 12.
    Cook S, Wenaweser P, Togni M. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation. 2007;115:2426–34.CrossRefPubMedGoogle Scholar
  13. 13.
    Tada T, Byrne RA, Simunovic I. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patiens. JACC Cardiovasc Interv. 2013;6:1267–74.CrossRefPubMedGoogle Scholar
  14. 14.
    Raber L, Magro M, Stefanini GG. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation. 2012;125:1110–21.CrossRefPubMedGoogle Scholar
  15. 15.
    Nakazawa G, Vorpahl M, Finn AV, Narula J, Virmani R. One step forward and two steps back with drug-eluting stents: from preventing restenosis to causing late thrombosis and nouveau atherosclerosis. JACC Cardiovasc Imaging. 2009;2:625–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Alfonso F, Fernandez-Viña F, Medina M. Neoatherosclerosis: the missing link between very late stent thrombosis and very late in-stent restenosis. J Am Coll Cardiol. 2013;61:155.CrossRefGoogle Scholar
  17. 17.
    Bastante T, Rivero F, Cuesta J. Bioresorbable vascular scaffold for very late stent thrombosis resulting from ruptured neoatherosclerosis. Rev Port Cardiol. 2015;34:779.CrossRefPubMedGoogle Scholar
  18. 18.
    Armstrong EJ, Feldman DN, Wang TY. Clinical presentation, management, and outcomes of angiographically documented early, late and very late stent thrombosis. JACC Cardiovasc Interv. 2012;5:131–40.CrossRefPubMedGoogle Scholar
  19. 19.
    Biondi-Zoccai GG, Agostoni P, Sangiorgi GM. Incidence, predictors, and outcomes of coronary dissections left untreated after drug-eluting stent implantation. Eur Heart J. 2006;27:540–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Alfonso F, Bastante T, Cuesta J. Drug-coated balloon treatment of very late stent thrombosis due to complicated neoatherosclerosis. Arq Bras Cardiol. 2016;106:541–3.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Berry C, Tardif JC, Bourassa MG. Coronary heart disease in patient with diabetes. Part II: recent advances in coronary revascularization. J Am Coll Cardiol. 2007;49:643–56.CrossRefPubMedGoogle Scholar
  22. 22.
    Wiviott SD, Braunwald E, Angiolillo DJ. Greater clinical benefict of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel – thrombolysis in myocardial infarction 38. Circulation. 2008;118:1626–36.CrossRefPubMedGoogle Scholar
  23. 23.
    Dangas GD, Claessen BE, Mehran R. Stent thrombosis after primary angioplasty for STEMI in relation to non-adherence to dual antiplatelet therapy over time: results of the HORIZONS-AMI trial. EuroIntervention. 2013;8(9):1033.CrossRefPubMedGoogle Scholar
  24. 24.
    Ellis SG, Kereiakes DJ, Metzger DC, ABSORB III Investigators. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015;373(20):1905–15.CrossRefPubMedGoogle Scholar
  25. 25.
    Toyota T, Morimoto T, Shiomi H. Very late scaffold thrombosis of bioresorbable vascular scaffold: systematic review and a meta-analysis. JACC Cardiovasc Interv. 2017;10:27–37.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Javier Cuesta
    • 1
  • Marcos García-Guimaraes
    • 1
  • Fernando Rivero
    • 1
  • Teresa Bastante
    • 1
  • Fernando Alfonso
    • 1
  1. 1.Department of Cardiology, Hospital Universitario de La PrincesaUniversidad Autónoma de MadridMadridSpain

Personalised recommendations